Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies
Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific antigens from previously uncharted genomic dark matter. The round was led by Pfizer’s and Merck KGaA’s respective investment arms, who …